Brief: Belite Bio Says Interim Data From "Dragon" Trial Expected In Q4 2024
12/03/2024 02:17
March 11 (Reuters) - Belite Bio Inc BLTE.O :
* BELITE BIO REPORTS FOURTH QUARTER AND FULL YEAR 2023
FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATE
* INTERIM DATA FROM "DRAGON" TRIAL EXPECTED IN 4Q 2024
* PRIMARY EFFICACY ENDPOINT IS SLOWING OF ATROPHIC LESION
GROWTH
RATE; SAFETY AND TOLERABILITY WILL ALSO BE ASSESSED FOR DRAGON
Source text for Eikon: ID:nGNX8ljnzq
Further company coverage: BLTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses